Schizophrenia and Psychoses

Latest News

Polygenic Risk Scores Predict Progression to Other Disorders in Unipolar Depression

By

Emily Pond

Publish Date July 28, 2020

Polygenic risk scores predict the progression from unipolar depression to bipolar or psychiatric disorders.

Long-Acting Injectable Antipsychotics May Delay Time to First Hospitalization in Early-Phase Schizophrenia

By

Nicole Bowens, PhD

Publish Date July 27, 2020

Compared with usual treatment, the use of long-acting injectable antipsychotics significantly increased the time to first hospitalization in patients with early-phase schizophrenia.

Sublingual Dexmedetomidine Promising for Acute Agitation With Schizophrenia, Bipolar Disorder

By

Brian Park, PharmD

Publish Date July 22, 2020

Dexmedetomidine is currently available as a solution for intravenous infusion for use in clinical anesthesia and sedation in an intensive care setting.

Feasibility of Treating Adolescents With First Episode Psychosis Using Antipsychotic Medication or Psychological Intervention

By

Jessica Nye

Publish Date July 17, 2020

Adverse events, including voluntary psychiatric admission, suicide attempt, serious violent incident, voluntary admission to a general medical ward, overdose of medication or painkillers, were highest among the combined group compared to the monotherapies.

Suicide Rate Up for Schizophrenia Spectrum Disorders

Publish Date July 6, 2020

Predictors of suicide death include male sex, later age at first diagnosis, prior mood disorder diagnosis

Psychiatric Disorders May Share Common Neurodevelopmental Cortical Thinning Patterns

By

Jessica Nye

Publish Date June 30, 2020

The researchers concluded that the correlation between interregional cortical thinning during maturation and expression patterns of genes associated with multiple psychiatric disorders suggested a common molecular process.

Emotion Dysregulation Mediates the Effects of Trauma on Depression, Positive Symptoms in Psychosis

By

Emily Pond

Publish Date June 26, 2020

Maladaptive cognitive emotion regulation and global emotion dysregulation emerged as mediators of the effects of trauma on depressive and positive symptoms in early nonaffective psychosis.

Pimavanserin sNDA Submitted for Dementia-Related Psychosis

By

Brian Park, PharmD

Publish Date June 23, 2020

Acadia Pharmaceuticals has submitted a supplemental New Drug Application to the FDA for pimavanserin (Nuplazid®) for the treatment of hallucinations and delusions associated with dementia-related psychosis.

Schizophrenia Polygenic Risk Elevated with Parvalbumin Interneuron Variation

By

Laurel Ranger

Publish Date June 22, 2020

Data from animal models and postmortem tissue analysis indicate that interneuron dysfunction is an essential feature of schizophrenia.

Phase 3 Trial Evaluating Roluperidone in Schizophrenia Misses End Points

By

Brian Park, PharmD

Publish Date June 8, 2020

Minerva Neurosciences announced that its phase 3 trial of roluperidone (MIN-101) did not meet the primary and key secondary end points for the treatment of negative symptoms in schizophrenia.